Bio-rad Laboratories Inc (BIO) Q1 2019 10-Q Quarterly Earnings

Short answer

Bio-rad Laboratories Inc (BIO) filed its Q1 2019 10-Q quarterly report on May 10, 2019 for the quarter ended Mar 31, 2019.

AI summary of MD&A and risk factor updates

Revenue $554.0M, up 0.4% YoY from $551.5M, with currency-neutral growth of 4.0%
Gross margin 56.3% vs 54.8% YoY, while net income margin 156.2% vs 119.1%
Best segment Life Science revenue $215.7M, up 9.1%; Clinical Diagnostics worst, $334.1M, down 4.8%
Cash and investments $859.0M; operating cash flow $42.9M vs $40.3M YoY
$16.0M acquisition payment in March; government spending constraints, trade disputes and regulation posed growth risks

New executive-management risk: COO appointed April 22, 2019 and CFO April 6, 2019, potentially disrupting operations
Regulatory risk: Brexit may add United Kingdom-European Union product, personnel, and compliance complexities
Near-term operational risk: ERP implementation delays previously disrupted manufacturing, logistics, invoicing, and shipments
Financial risk: $439.4 million outstanding indebtedness and $200.0 million revolving facility, with $0.2 million used for standby letters of credit
Currency risk: foreign subsidiaries generated 59% of net sales, exposing results to U.S. dollar fluctuations

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Compare quarters, check guidance or see what insiders and funds did around the report.